Stephane Bancel Sells 40,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $133.68, for a total value of $5,347,200.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $723,468,941.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, August 24th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $142.21, for a total value of $5,688,400.00.
  • On Wednesday, August 17th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $159.03, for a total value of $6,361,200.00.
  • On Wednesday, August 10th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $172.29, for a total value of $6,891,600.00.
  • On Thursday, August 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $192.94, for a total value of $7,717,600.00.
  • On Thursday, July 28th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $156.73, for a total value of $6,269,200.00.
  • On Thursday, July 21st, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $168.11, for a total value of $6,724,400.00.
  • On Wednesday, July 13th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $172.69, for a total value of $6,907,600.00.
  • On Thursday, July 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $171.00, for a total value of $6,840,000.00.
  • On Thursday, June 30th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $143.21, for a total value of $5,728,400.00.
  • On Wednesday, June 22nd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $136.58, for a total value of $5,463,200.00.

Moderna Stock Up 0.7 %

Moderna stock opened at $142.28 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.99 and a quick ratio of 1.71. The stock has a market capitalization of $56.59 billion, a price-to-earnings ratio of 4.34, a PEG ratio of 0.78 and a beta of 1.69. Moderna, Inc. has a 1-year low of $115.61 and a 1-year high of $464.85. The business has a fifty day moving average price of $158.67 and a 200-day moving average price of $151.50.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. The firm had revenue of $4.73 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $6.46 EPS. Equities research analysts forecast that Moderna, Inc. will post 26.42 EPS for the current fiscal year.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Keybank National Association OH lifted its position in Moderna by 22.1% during the 1st quarter. Keybank National Association OH now owns 2,877 shares of the company’s stock worth $496,000 after acquiring an additional 521 shares during the period. Fieldpoint Private Securities LLC lifted its position in Moderna by 103.8% during the 1st quarter. Fieldpoint Private Securities LLC now owns 214 shares of the company’s stock worth $37,000 after acquiring an additional 109 shares during the period. Metis Global Partners LLC lifted its position in Moderna by 79.5% during the 1st quarter. Metis Global Partners LLC now owns 5,530 shares of the company’s stock worth $953,000 after acquiring an additional 2,450 shares during the period. Ellis Investment Partners LLC lifted its position in Moderna by 112.5% during the 1st quarter. Ellis Investment Partners LLC now owns 425 shares of the company’s stock worth $73,000 after acquiring an additional 225 shares during the period. Finally, Aviva PLC lifted its position in Moderna by 101.0% during the 1st quarter. Aviva PLC now owns 109,705 shares of the company’s stock worth $18,898,000 after acquiring an additional 55,118 shares during the period. Institutional investors and hedge funds own 60.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on MRNA shares. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “hold” rating to a “buy” rating and raised their price objective for the stock from $155.00 to $165.00 in a report on Wednesday. Morgan Stanley reduced their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a report on Thursday, August 4th. SVB Leerink lifted their price target on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a report on Monday, August 1st. Finally, Piper Sandler cut their price target on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $227.75.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.